GlassScriptPhysician profile
Rachel Shepherd
NPI 1568773166
$3,158.48
in general payments reported to CMS, 2019-2025
32 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $527 · 2021: $620 · 2022: $293 · 2023: $635 · 2024: $403 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.74 |
| Education | $104.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.95 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $334.78 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Therapeuticsmd, INC. | $303.29 | 2019-2022 | |
| Davol INC. | $268.45 | 2023-2024 | Phasix Mesh, Arista Ah Flexitip |
| Astellas Pharma US INC | $256.07 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $218.50 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $217.50 | 2022-2025 | |
| Lupin INC. | $125.07 | 2020 | |
| Dysis Medical, INC. | $120.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.28 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $90.53 | 2023-2024 | Ultomiris |
| Avion Pharmaceuticals | $71.00 | 2020-2021 | |
| Biogen, INC. | $60.01 | 2025 | Zurzuvae |
| Gynesonics, INC. | $52.21 | 2021 | |
| Exact Sciences Corporation | $48.66 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $45.27 | 2024-2025 | Intrarosa, Femlyv |
| Novo Nordisk INC | $43.65 | 2025 | Wegovy |
| Evofem Biosciences, INC. | $42.28 | 2021-2024 | |
| Dexcom, INC. | $39.12 | 2023 | Dexcom G6 Transmitter |
| Organon LLC | $28.60 | 2022 | |
| Kaleo, INC. | $19.35 | 2022 | |
| Becton, Dickinson and Company | $19.34 | 2024 | Arista Ah Flexitip |
| Coopersurgical, INC. | $18.84 | 2019 | |
| Duchesnay USA Incorporated | $18.73 | 2019 | |
| Lilly USA, LLC | $18.46 | 2024 | Zepbound |
| Innovation Technologies INC | $16.47 | 2025 | Irrisept |
| Pfizer INC. | $15.51 | 2024 | |
| Allergan, INC. | $13.44 | 2020 | |
| Aspira Women'S Health INC | $12.76 | 2024 | Ova1 |
| Avanos Medical | $11.75 | 2021 | |
| Channel Medsystems, INC. | $11.70 | 2024 | |
| Acessa Health INC. | $9.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.